Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Escherichia coli | DNA gyrase (type II topoisomerase), subunit A | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | DNA gyrase/topoisomerase IV, A subunit domain-containing protein | 0.0318 | 0.1792 | 1 |
Chlamydia trachomatis | DNA gyrase subunit A | 0.0318 | 0.1792 | 1 |
Echinococcus granulosus | vesicular acetylcholine transporter | 0.1185 | 0.765 | 1 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.0121 | 0.0464 | 0.0431 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0088 | 0.0241 | 0.0788 |
Leishmania major | mitochondrial DNA topoisomerase II | 0.0121 | 0.0464 | 0.0431 |
Plasmodium falciparum | DNA gyrase subunit A | 0.0318 | 0.1792 | 1 |
Mycobacterium ulcerans | DNA gyrase subunit A | 0.0318 | 0.1792 | 1 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0069 | 0.0109 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase subunit A | 0.0318 | 0.1792 | 1 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0069 | 0.0109 | 0.5 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0153 | 0.0677 | 0.2419 |
Plasmodium falciparum | DNA gyrase subunit B | 0.0153 | 0.0677 | 0.3378 |
Loa Loa (eye worm) | hypothetical protein | 0.0783 | 0.4937 | 0.4882 |
Brugia malayi | vesicular acetylcholine transporter unc-17 | 0.1185 | 0.765 | 0.7624 |
Echinococcus multilocularis | vesicular acetylcholine transporter | 0.1185 | 0.765 | 1 |
Loa Loa (eye worm) | vesicular acetylcholine transporter unc-17 | 0.1185 | 0.765 | 0.7624 |
Plasmodium vivax | DNA gyrase subunit B, putative | 0.0153 | 0.0677 | 0.3378 |
Treponema pallidum | DNA gyrase, subunit A (gyrA) | 0.0318 | 0.1792 | 1 |
Onchocerca volvulus | Vesicular acetylcholine transporter homolog | 0.1185 | 0.765 | 1 |
Plasmodium vivax | DNA gyrase subunit A, putative | 0.0318 | 0.1792 | 1 |
Mycobacterium leprae | Probable DNA gyrase (subunit A) GyrA (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (Type II DNA topoisomerase) | 0.0152 | 0.0668 | 1 |
Trypanosoma brucei | DNA topoisomerase ii | 0.0121 | 0.0464 | 0.0431 |
Mycobacterium tuberculosis | DNA gyrase (subunit A) GyrA (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.0318 | 0.1792 | 1 |
Giardia lamblia | DNA topoisomerase II | 0.0064 | 0.0076 | 0.5 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.0121 | 0.0464 | 0.0431 |
Schistosoma mansoni | vesicular acetylcholine transporter | 0.1185 | 0.765 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 300 nM | BindingDB_Patents: Fluorescence Polarisation Assay. In a black, 384-well polystyrene assay plate, 30 microliters/well of 5 nM Escherichia coli DNA gyrase A/B tetramer and 130 micrograms/ml of topologically relaxed plasmid containing the triplex-forming sequence TTCTTCTTCTTCTTCTTCTTCTTCTTC in an assay buffer consisting of 35 mM Tris-HCl (pH 7.5), 24 mM KCl, 4 mM MgCl2, 2 mM dithiothreitol, 1.8 mM spermidine, 5% (v/v) glycerol, 200 nM bovine serum albumin, 0.8% dimethylsulfoxide, and 0.3 mM ATP may be incubated at ambient temperature for (typically 30 minutes) in the absence or presence of 5-10 different concentrations of test compound. The supercoiling reactions may be quenched by the addition of 10 microliters/well of 40 nM oligodeoxynucleotide probe in 3x triplex-forming buffer consisting of 150 mM NaCl, and 150 mM sodium acetate at pH 3.5. The oligodeoxynucleotide probe may be 5x-BODIPY-FL-labeled TTCTTCTTC. After 60 minutes, the fluorescence anisotropy of the BODIPY-FL may be measured in a Tecan Ultra plate reader, using 485 nM. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.